Prostate

Evidence shows the benefit of higher radiation doses (dose escalation) in biochemical control of prostate cancer treated with external beam radiotherapy (EBRT). The downside of this is higher dose and therefore higher toxicity to adjacent organs. Rectal damage is the dose limiting toxicity for RT in prostate cancer and is difficult to avoid completely as doses to eradicate prostate cancer are higher than the dose that is toxic to the rectum. The ACCUSYTE™3D Fiducial Markers are implanted to target the tumor and deliver a high radiation dose sparing normal tissue, minimizing the dose to the surrounding organs, while ensuring high therapeutic doses are delivered to the prostate. Intensity modulated RT (IMRT) and volumetric modulated arc therapy (VMAT), have been developed to effectively treat prostate cancer, however; these techniques require tighter safety margins and accurate localization of the prostate is vital as prostate motion occurs during a course of EBRT.